Valuation: Prothena Corporation plc

Market Cap 448M 394M 368M 337M 631M 42.92B 647M 4.36B 1.7B 21.24B 1.68B 1.65B 73.43B P/E 2026 *
-119x
P/E 2027 * -8.7x
Enterprise Value 448M 394M 368M 337M 631M 42.92B 647M 4.36B 1.7B 21.24B 1.68B 1.65B 73.43B EV / Sales 2026 *
5.38x
EV / Sales 2027 * 20.4x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day-2.45%
1 week-2.93%
Current month-15.42%
1 month-15.42%
3 months-25.14%
6 months-6.02%
Current year-13.30%
1 week 8.26
Extreme 8.255
9.13
1 month 8.08
Extreme 8.075
10.15
Current year 7.73
Extreme 7.73
11.8
1 year 6.61
Extreme 6.61
11.8
3 years 4.32
Extreme 4.32
70.09
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Buy 50,000 0.0955%
02/06/26 Buy 50,000 0.0955%
28/07/25 Free

Chief Technology Officer

85,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-2.39%-2.93%+20.35%-87.98% 448M
-3.74%-6.32%+42.70%+63.37% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.82%+0.20%-16.18%-15.27% 23.51B
-3.19%-7.16%-5.20%+351.40% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.15%+26.00%-33.84% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
-0.17%-1.09%+49.36%+179.27% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -2.46%-1.25%+33.05%+131.31% 23.8B
Weighted average by Cap. -2.38%-0.46%+30.24%+120.45%

Financials

2026 *2027 *
Net sales 83.32M 73.21M 68.34M 62.72M 117M 7.98B 120M 810M 317M 3.95B 313M 306M 13.65B 22M 19.33M 18.04M 16.56M 31M 2.11B 31.76M 214M 83.68M 1.04B 82.6M 80.81M 3.6B
Net income 2.42M 2.13M 1.99M 1.82M 3.41M 232M 3.5M 23.57M 9.22M 115M 9.1M 8.9M 397M -55.93M -49.14M -45.87M -42.1M -78.8M -5.36B -80.75M -544M -213M -2.65B -210M -205M -9.16B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
30/07/26 $8.275 -3.33% 118,289
29/07/26 $8.560 0.00% 641,215
28/07/26 $8.560 -1.61% 802,255
27/07/26 $8.700 -0.57% 704,707
24/07/26 $8.750 +2.58% 576,837
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.560USD
Average target price
21.40USD
Spread / Average Target
+150.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock